328 related articles for article (PubMed ID: 17884403)
1. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
Tsuji K; Tsutani K
Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
[TBL] [Abstract][Full Text] [Related]
2. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
Tsuji K; Tsutani K
J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
[TBL] [Abstract][Full Text] [Related]
3. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529
[TBL] [Abstract][Full Text] [Related]
4. Delays in new drug applications in Japan and industrial R&D strategies.
Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
[TBL] [Abstract][Full Text] [Related]
5. Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison.
Reichert JM; Healy EM
Eur J Pharm Biopharm; 2001 Jan; 51(1):1-7. PubMed ID: 11154897
[TBL] [Abstract][Full Text] [Related]
6. Biopharmaceuticals: recent approvals and likely directions.
Walsh G
Trends Biotechnol; 2005 Nov; 23(11):553-8. PubMed ID: 16051388
[TBL] [Abstract][Full Text] [Related]
7. The notorious "drug lag" for oncology drugs in Japan.
Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
[TBL] [Abstract][Full Text] [Related]
8. Prices and availability of biopharmaceuticals: an international comparison.
Danzon PM; Furukawa MF
Health Aff (Millwood); 2006; 25(5):1353-62. PubMed ID: 16966733
[TBL] [Abstract][Full Text] [Related]
9. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
Kawabata-Shoda E; Masuda S; Kimura H
J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002.
Reichert JM; Paquette C
Curr Opin Mol Ther; 2003 Apr; 5(2):139-47. PubMed ID: 12772503
[TBL] [Abstract][Full Text] [Related]
11. Personal imports of drugs to Japan in 2005--an analysis of import certificates.
Tsuji K; Tsutani K
J Clin Pharm Ther; 2008 Oct; 33(5):545-52. PubMed ID: 18834370
[TBL] [Abstract][Full Text] [Related]
12. Trends in development and approval times for new therapeutics in the United States.
Reichert JM
Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576
[TBL] [Abstract][Full Text] [Related]
13. Overview of the clinical application of regenerative medicine products in Japan.
Tsubouchi M; Matsui S; Banno Y; Kurokawa K; Kawakami K
Health Policy; 2008 Oct; 88(1):62-72. PubMed ID: 18395290
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.
Kaitin KI; DiMasi JA
Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382
[TBL] [Abstract][Full Text] [Related]
15. Researchers see a need for speed in EU trial approvals.
Cressey D
Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580
[No Abstract] [Full Text] [Related]
16. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
[TBL] [Abstract][Full Text] [Related]
17. The drug lag: new drug introductions in India in comparison to United States.
Karan RS; Malhotra S; Pandhi P
J Assoc Physicians India; 2002 Jun; 50():782-7. PubMed ID: 12240842
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the success rates of new drug development in Japan and the lag behind the US.
Hirai Y; Yamanaka Y; Kusama M; Ishibashi T; Sugiyama Y; Ono S
Health Policy; 2012 Mar; 104(3):241-6. PubMed ID: 22172246
[TBL] [Abstract][Full Text] [Related]
19. Drug lag for cardiovascular drug approvals in India compared with the US and EU approvals.
Kataria BC; Mehta DS; Chhaiya SB
Indian Heart J; 2013; 65(1):24-9. PubMed ID: 23438609
[TBL] [Abstract][Full Text] [Related]
20. Patent holdings of US biotherapeutic companies in major markets.
Sebastian TE; Yerram CB; Saberwal G
Drug Discov Today; 2009 May; 14(9-10):442-5. PubMed ID: 19429502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]